Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance

Oestrogen receptor (ER) positive breast cancer (BC) patients are eligible for endocrine therapy (ET), regardless of ER immunohistochemical expression level. There is a wide spectrum of ER expression and the response to ET is not uniform. This study aimed to assess the clinical and molecular conseque...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2024-01, Vol.197, p.113473-113473, Article 113473
Main Authors: Makhlouf, Shorouk, Quinn, Cecily, Toss, Michael, Alsaleem, Mansour, Atallah, Nehal M, Ibrahim, Asmaa, Rutland, Catrin S, Mongan, Nigel P, Rakha, Emad A
Format: Article
Language:English
Subjects:
Breast Neoplasms - drug therapy
Female
Humans
Prognosis
Receptors, Estrogen - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oestrogen receptor (ER) positive breast cancer (BC) patients are eligible for endocrine therapy (ET), regardless of ER immunohistochemical expression level. There is a wide spectrum of ER expression and the response to ET is not uniform. This study aimed to assess the clinical and molecular consequences of ER heterogeneity with respect to ET-response. ER expression, categorised by percentage and staining intensity in a large BC cohort (n = 7559) was correlated with clinicopathological parameters and patient ET response. The Cancer Genome Atlas Data BC cohort (n = 1047) was stratified by ER expression and transcriptomic analysis completed to better understand the molecular basis of ER heterogeneity. The quantitative proportional increase in ER expression was positively associated with favourable prognostic parameters. Tumours with 1-9% ER expression were characteristically similar to ER-negative (
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2023.113473